Skip to main content

Ovarian Cancer

Quality of Life Maintained with Niraparib in Newly Diagnosed Ovarian Cancer

Several Resources Offer Helpful Information on COVID-19 for Cancer Patients

PARP Inhibitors Consistently Improve PFS as First-Line Maintenance in Advanced Ovarian Cancer

Immunotherapy Triplet Has Significant Clinical Activity in Recurrent Ovarian Cancer

Online PARP Inhibitor Education Has Positive Impact on Oncologists’ and OB/GYNs’ Knowledge and Confidence

Prepare for Side Effects with Use of PARP Inhibitors as Upfront Maintenance

Upfront Maintenance Combination for Advanced Ovarian Cancer Not Ready for Clinical Use

No Difference in Overall Survival Between Nivolumab and Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer

Triplet Including Folate Receptor Alpha Antibody–Drug Conjugate Has Activity in Recurrent Ovarian Cancer

Copay Maximizer Programs Replacing Accumulator Programs with Ramifications for Patient Out-of-Pocket Expenses

4
5
6
7
8
9
10

Page 7 of 13
Results 61 - 70 of 125